References
- Fu C, Gombos DS, Lee J, et al. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 2017;8:58709–58727. doi:https://doi.org/10.18632/oncotarget.17634.
- Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018;38:1063–1078. doi:https://doi.org/10.1097/IAE.0000000000002181.
- Niro A, Recchimurzo N, Sborgia A, Guida M, Alessio G. Bilateral ischemic retinal vasculitis in metastatic cutaneous melanoma patient treated with Dabrafenib and Trametinib: a case report. Ocul Immunol Inflamm. 2018;26:783–785. doi:https://doi.org/10.1080/09273948.2016.1261166.
- Draganova D, Kerger J, Caspers L, Willermain F. Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. J Ophthalmic Inflamm Infect. 2015;5:17. doi:https://doi.org/10.1186/s12348-015-0049-9.
- Lim J, Lomax AJ, McNeil C, Harrisberg B. Uveitis and papillitis in the setting of Dabrafenib and Trametinib therapy for metastatic melanoma: a case report. Ocul Immunol Inflamm. 2018;26:628–631. doi:https://doi.org/10.1080/09273948.2016.1246666.
- Joshi L, Karyis A, Gemenetzi M, Shao EH, Taylor SR. Uveitis as a result of MAP kinase pathway inhibition. Case Rep Ophthalmol. 2013;4:279–282. doi:https://doi.org/10.1159/000357060.
- Rueda-Rueda T, Sanchez-Vicente JL, Moruno-Rodriguez A, Molina-Socola FE, Martinez-Borrego AC, Lopez-Herrero F. Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib. Arch Soc Esp Oftalmol. 2018;93:458–462. doi:https://doi.org/10.1016/j.oftal.2018.01.008.
- Krisl JC, Doan VP. Chemotherapy and transplantation: the role of immunosuppression in malignancy and a review of antineoplastic agents in solid organ transplant recipients. Am J Transplant. 2017;17:1974–1991. doi:https://doi.org/10.1111/ajt.2017.17.issue-8.
- Ben-Betzalel G, Baruch EN, Boursi B, et al. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma. Eur J Cancer. 2018;101:229–235. doi:https://doi.org/10.1016/j.ejca.2018.06.030.
- Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with Nivolumab and Ipilimumab because of adverse events: a pooled analysis of randomized Phase II and III trials. J Clin Oncol. 2017;35:3807–3814. doi:https://doi.org/10.1200/JCO.2017.73.2289.